Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | HPGD | P15428 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.83 |
| ▸ | CA2 | P00918 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.83 |
| ▸ | AQP1 | P29972 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230554 | 0.93 | KDM4E (0.84) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL230651 | 0.92 | KDM4E (0.86) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL11784497 | 0.91 | KDM4E (0.81) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL22971474 | 0.91 | KDM4E (0.81) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL29388271 | 0.91 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL27525 | 0.91 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL4425232 | 0.91 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL2876098 | 0.90 | KDM4E (0.80) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL11788796 | 0.90 | KDM4E (0.80) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| SCHEMBL27827714 | 0.90 | KDM4E (0.80) | KDM4EUSP2ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 2228/4885USP2 3353/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.